• Presented at 19th Congress of the European Crohn’s and Colitis Organisation (2023)

  • Collaborator: Takeda

  • Authors: Marjorie Argollo, Yoon-KyoAn, Domingo C. Balderramo, Nahla Azzam, Chia-Jung Kuo,
    Olga Fadeeva, Elenore Uy

Immunosuppressants and biologics are the mainstay of treatment in patients with inflammatory
bowel disease (IBD). Understanding patient preferences informs treatment decision-making and
may optimize treatment acceptance and adherence. There is a lack of evidence regarding
preferences towards treatment attributes among patients with IBD from non-Western countries.
This study aims to describe the preferences of patients with Crohn’s disease (CD) and ulcerative
colitis (UC) towards the attributes of treatment with advanced therapies for IBD, including safety
and efficacy profiles, frequency and route of administration (RoA) in a real-world setting from
5 countries – Argentina, Australia, Brazil, Saudi Arabia and Taiwan